Clinical Trial

Neonatal Platelet Transfusion Threshold Trial

Study acronym: NeoPlaTT
Recruiting
View on ClinicalTrials.gov →
Summary
The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0/7 to 26 6/7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0/7 weeks' postmenstrual age (PMA).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2024-11-04; most recent amendment 2026-03-24.
Status change: Not Yet Recruiting → Recruiting 2025-05-08
Trial Details
NCT Number NCT06676904
Lead Sponsor NICHD Neonatal Research Network
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Thrombocytopenia, Neonatal, Platelet Transfusion, Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Thrombosis
Enrollment 2,433 participants
Start Date 2025-06-13
Primary Completion 2031-01-31 (estimated)
Study Completion 2031-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-25